Impact Of Early Adoption Research Articles

The Impact of Early Adoption of IFRS on the Quality of Accounting Information

After the various financial scandals, the debate concerning accounting information has been renewed in earnest. Consequently, we have decided to study the quality of accounting information. Indeed the aim of this article, which spans from the period of 2002 to 2006, is to study the impact of early adoption of IFRS (International Financial Reporting Standards) on the quality of accounting information. After reviewing the literature, we chose to study the following aspects:earnings managment and timely loss recognition. This study deals with as ample of the CAC (Cotation Assistee en Continu: Scoring Assisted Continuous) 40 companies. Panel number one is made up of companies that foresaw the adoption of IFRS. Panel number two consist of companies that waited for the legal date for the adoption of IFRS. After empirical tests, we noticed that for panel number one, the quality of accounting information has improved; while in panel number two, we noticed an increase in earnings managment. In conclusion, not foreseeing the adoption of IFRS hampers the companies and increases earning management.

Early Adoption of Innovative Analytical Approach and Its Impact on Organizational Analytics Maturity and Sustainability: A Longitudinal Study from a U.S. Pharmaceutical Company

We investigate the impact of early adoption of an innovative analytics approach on organizational analytics maturity and sustainability. With the sales operation planning involving the accurate determination of physician detailing frequency, multiple product sequencing, nonlinear promotional response functions and achievement of the right level of share of voice (SOV), an analytical approach was developed by integrating domain knowledge, neural network (NN)’s pattern-recognition capability and nonlinear mathematical programming to address these challenges. A pharmaceutical company headquartered in the U.S. championed this initial research in 2005 and became the first major firm to implement the recommendations. The company improved its profitability by 12% when piloted to a sales district with 481 physicians; then it launched this approach nationally. In 2014, the firm again gave us its data, performance of the analytical approach and access to key stakeholders to better understand the changes in the pharmaceutical sales operations landscape, the firm’s analytics maturity and sustainability of analytics. Results suggest that being the early adopter of innovation doubled the firm’s technology utilization from 2005 to 2014, as well as doubling the firm’s ability to continuously improve the sales operations process; it outperformed the standard industry practice by 23%. Moreover, the infusion of analytics from the corporate office to sales, improvement in management commitment to analytics, increased communications for continuous process improvement and the successes from this approach has created the environment for sustainable organizational growth in analytics.

PD06-08: Projecting the Impact of Adopting Trial Results

Abstract Background: There is often a substantial delay between the presentation of clinical trial results and change in practice. Reasons for slow adoption include the disruption of practice routines, doubt about the validity of results, financial disincentive, and resistance to change. We propose a decision-making process to inform adoption that considers three factors: likelihood the trial's conclusions will not change with longer follow up, and consequences of early and late adoption. We apply this framework to the published 4-year results of the international TARGIT-A trial, which compares intraoperative radiation therapy (IORT) to external beam radiation therapy (EBRT). Methods: To find whether the trial results will remain robust, we reviewed the TARGIT-A trial's annual hazards for local recurrence (LR). We then reviewed 5–10 year LR rates from recent clinical trials with similar patient populations undergoing RT, no RT or partial breast RT. To assess the impact of an early change in practice, a Markov model was used to evaluate life expectancy, quality adjusted life years (QALYs), and cost. Sensitivity analysis estimated the impact of varying the LR rate 1–20x the TARGIT-A 4 year results. To estimate the impact of late adoption, we generated the expected number of N0, grades 1 & 2, ductal cancers in postmenopausal women (>50 yrs) from SEER and US Census Bureau data. Using Medicare rates, costs of EBRT vs. IORT were compared and potential savings to the health care system calculated. Results: The TARGIT-A peak hazard for LR for IORT and EBRT occurred at 3 years. In the START and ATAC trials, the peak local recurrence Kaplan Meier estimates are between 2 and 3 years. In other trials (ATAC, and in the 2005 RT Lancet overview) there is no second peak of recurrence, making it unlikely that longer follow up will change the conclusion of the TARGIT-A results. The LRR in similar trials have dropped steadily over time for post menopausal, stage I patients with or without RT. Impact of early adoption: If treatment were adopted early, the impact on life expectancy and QALYs would be minimal unless IORT LR rate exceeds 20% over a 10 year period of time. Impact of late adoption: In the US, 45% of new breast cancer cases fit the described population. EBRT costs $6,400 more than IORT per patient on average. If adoption were delayed 5 years to allow the trial results to mature, 70,136 patients per year are expected to receive EBRT resulting in a societal burden of >$2.2 billion barring the capital investment required for new technology. This also assumes that patients have equal utility for a single dose of IORT as they do for 3–6 weeks of postoperative radiation therapy. If IORT utility is higher than that of EBRT, then the IORT strategy is both more effective and less costly. Conclusion: The process of modeling the impact of both early and late adoption when considering the stability of trial results can serve as a tool to evaluate whether to change practice. This analysis was tested on the results of the TARGIT-A trial, and demonstrated that prompt adoption of the IORT intervention would cause minimal harm, provide an improved quality of life, and offer significant societal savings. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD06-08.

Impact of early adoption of systemic treatment modalities on mortality trends of breast cancer in Canada – implications for cancer organization processes

Impact of early adoption of systemic treatment modalities on mortality trends of breast cancer in Canada – implications for cancer organization processes